Cytovation
Manufacturing · Norway · 1-10 Employees
View Company Info for Free
Overview
Headquarters
Solheimsgaten 11, Bergen, 5058, NorwayPhone Number
+44 2070674300Website
www.cytovation.comRevenue
<$5 MillionIndustry
ZI Rank: 1
Signal Type
Dec
Jan
Feb
Mar
Apr
May
ZI Rank
1
1
1
1
1
1
About Cytovation
Cytovation builds on over 15 years of cutting-edge research from two leading Norwegian institutions; University of Bergen and Haukeland University Hospital. Led by a highly experienced management team and world-renowned experts in tumor biology, an extensive research program focused on engineering synthetic peptides with unique properties. CyPep-1, the company's lead candidate, is being developed as a first-in-class lytic agent for the treatment of solid tumors in both injectable and cream formulations. Through its unique pharmacological properties, CyPep-1 selectively targets and lyses tumor cell membranes based on their altered molecular composition. This mode of action kills cancer cells, releases tumor antigens, and potentially induces a tumor-specific immune response by in-situ immunization.Explore more
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Cytovation your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Check if Cytovation has recently received funding, and reach out quickly before it becomes old news!
Product Launch: Get notified when Cytovation launches new products
Funding: Get notified immidiatlly once Cytovation has new funding data
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Website visits: Recent activity has been detected on your website
Cytovation, which may be a good buyer, showed buying intent in Masked Content Topic
Earning: See what the market has to say on Cytovation recently announced quarterly report
Click to see if Cytovation had a recent Job posting/layoffs
Congratulate Masked Content for being promoted to Masked Content at Cytovation
Check out if Cytovation is spiking on competitors!
Recommended Actions
Find VP level buyers at Cytovation
Find 2 more new buyers
Company Profile Activity
Activity Insights
Cytovation is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Cytovation is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Cytovation.
Cytovation financials insights
Gather financial insights about Cytovation, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2017
Private Equity
$2.4M
2023
Series A
$28M
Cytovation Tech Stack
A closer look at the technologies used by Cytovation
Most Recent Scoops
Event
Product Marketing, Events, Learning & Development, Software, Bioengineering, Pharmaceuticals, Public Health, Field /Outside Sales, Field Marketing, Healthcare Technology, Patient Experience
Funding
New Hire
Executive Move
Funding
Cytovation News & Media
Cytovation to Advance Development of CY-101 for Cancers Driven by Dysfunction of Wnt/β-catenin Signalling Under International Nonproprietary Name of Getacatetide
Bergen, Norway, July 23, 2025 – Cytovation ASA, a clinical stage oncology company focused on the development of its first-in-class bifunctional peptide CY-101, announces that the International Nonproprietary Names (INN) Expert Committee of the World Health Organization (WHO-INN) has approved "getacatetide" as the International Nonproprietary Name (INN) of CY-101.Cytovation Raises US$6m to Advance Phase 2 Development of CY-101 in Adrenocortical Carcinoma to First Clinical Readouts
New funds provided largely by existing investors, led by Sandwater Phase 2 trial to be delivered through novel agreement between Cytovation, Cancer...Cytovation Appoints Martin Dewhurst to its Board of Directors
Bergen, Norway, February 12, 2025 – Cytovation ASA, a clinical stage oncology company focused on the development of its first-in-class bifunctional peptide CY-101, announces the appointment of Mr. Martin Dewhurst to its Board of Directors.Cancer Research UK, Cytovation and the Norwegian Cancer Society collaborate to advance treatment for rare cancer
LONDON, UK, and BERGEN and OSLO, Norway, 23 January 2025 – Cancer Research UK, Cytovation and the Norwegian Cancer Society have signed an agreement to bring Cytovation’s lead asset, CY-101, into a multi-national Phase 2 clinical trial for patients with adrenocortical carcinoma (ACC).
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Cytovation
Sign Up For FreeTo access detailed company insights
Cytovation builds on over 15 years of cutting-edge research from two leading Norwegian institutions; University of Bergen and Haukeland University Hospital. Led by a highly experienced management team and world-renowned experts in tumor biology, an extensive research program focused on engineering synthetic peptides with unique properties. CyPep-1,... Read More
